{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:16:02Z","timestamp":1788196562781,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatments for non-small cell lung cancer (NSCLC) patients with EGFR mutations, but resistance inevitably develops. While resistance mechanisms in classical mutations are well studied, those in nonclassical mutations remain unclear. As a widely used EGFR-TKI, afatinib\u2019s resistance mechanisms in nonclassical mutations warrant further investigation to improve clinical outcomes. This study included NSCLC patients from multiple hospitals with nonclassical mutations who were finally resistant to afatinib. Baseline information and samples, including peripheral blood, tissue, and pleural fluid, were obtained for panel gene testing to identify potential gene mutations of resistance. A total of 21 eligible patients were included in this study. EGFR-related gene mutations accounted for 29.7% of all mutations, with TP53 accounting for 16.6%, other genes accounting for 41.5%, and MET amplification 2.7%. What we found different from classical mutations was that T790M mutation was the highest proportion in this study, followed by A767V, L858R, R776G. Concretely, T790M accounted for 7.8%, while A767V, L858R, R776G for 4.8% each, then NF1, CDK4 amplification and ALK accounted for 3.3%, 3.2% and 2.4%, respectively. This study represents the latest investigation of resistance mechanisms to afatinib in NSCLC patients with nonclassical mutations. The mechanism of resistance to EGFR-TKI in this study was discovered different from that of patients with classical mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049283","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:02:22Z","timestamp":1781600542000},"page":"e49283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism of afatinib resistance in non-small cell lung cancer patients with nonclassical EGFR mutations: A multicenter, retrospective study"],"prefix":"10.1097","volume":"105","author":[{"given":"Ranpu","family":"Wu","sequence":"first","affiliation":[{"name":"School of Medicine, Southeast University, Nanjing, Jiangsu, China"},{"name":"Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nanjing Chest Hospital, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiration, Nanjing Chest Hospital, No.215, Guangzhou Road, Gulou District, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Changzhou Cancer Hospital, No.68, Honghe Road, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Jiangsu University, 438, Jiefang Road, Zhenjiang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Respiratory Disease, Affiliated People\u2019s Hospital of Jiangsu University, No. 8, Dianli Road, Zhenjiang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiration, The Affiliated Huai\u2019an No.1 People\u2019s Hospital of Nanjing Medical University. No.1, Huanghexi Road, Huaiyin District, Huai\u2019an, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiudi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine, Southeast University, Nanjing, Jiangsu, China"},{"name":"Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Southeast University, Nanjing, Jiangsu, China"},{"name":"Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260831","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment.","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/bjc.2016.372","article-title":"Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.","volume":"115","author":"Kuiper","year":"2016","journal-title":"Br J Cancer"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","article-title":"A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.","volume":"114","author":"Tu","year":"2017","journal-title":"Lung Cancer"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1634\/theoncologist.2018-0572","article-title":"Genomic signature of driver genes identified by target next-generation sequencing in chinese non-small cell lung cancer.","volume":"24","author":"Wen","year":"2019","journal-title":"Oncologist"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy.","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"90557","DOI":"10.18632\/oncotarget.21164","article-title":"Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3892\/ol.2025.15121","article-title":"EGFR mutations in non-small cell lung cancer: Classification, characteristics and resistance to third-generation EGFR-tyrosine kinase inhibitors (Review).","volume":"30","author":"Tian","year":"2025","journal-title":"Oncol Lett"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations in NSCLC-A systematic review.","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J Thorac Oncol"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann Oncol"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.lungcan.2018.11.018","article-title":"Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.","volume":"127","author":"Tanaka","year":"2019","journal-title":"Lung Cancer"},{"key":"R15-20260831","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations.","volume":"36","author":"Mok","year":"2018","journal-title":"J Clin Oncol"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2019.06.025","article-title":"Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.","volume":"119","author":"Chang","year":"2019","journal-title":"Eur J Cancer"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s12325-021-01696-9","article-title":"Afatinib as first-line treatment in asian patients with EGFR mutation-positive NSCLC: a narrative review of real-world evidence.","volume":"38","author":"Lu","year":"2021","journal-title":"Adv Ther"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"834704","DOI":"10.3389\/fonc.2022.834704","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report.","volume":"12","author":"Yang","year":"2022","journal-title":"Front Oncol"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.21037\/jtd-21-1924","article-title":"Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.","volume":"14","author":"Tankere","year":"2022","journal-title":"J Thorac Dis"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1186\/s12885-019-5913-9","article-title":"Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.","volume":"19","author":"Chantharasamee","year":"2019","journal-title":"BMC Cancer"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cllc.2017.05.016","article-title":"Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR Mutations: a post hoc analysis of the BE-POSITIVE study.","volume":"19","author":"Pilotto","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R24-20260831","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11523-018-0612-z","article-title":"Liquid-biopsy-based identification of EGFR T790M mutation-mediated resistance to afatinib treatment in patients with advanced EGFR mutation-positive NSCLC, and subsequent response to osimertinib.","volume":"14","author":"Hochmair","year":"2019","journal-title":"Target Oncol"},{"key":"R25-20260831","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov"},{"key":"R26-20260831","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.18632\/oncotarget.7189","article-title":"The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"R27-20260831","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jtho.2016.06.032","article-title":"Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies.","volume":"11","author":"Campo","year":"2016","journal-title":"J Thorac Oncol"},{"key":"R28-20260831","first-page":"CD010383","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.","volume":"3","author":"Greenhalgh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R29-20260831","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.cllc.2017.07.002","article-title":"Clinical factors predicting detection of T790M mutation in rebiopsy for EGFR-mutant non-small-cell lung cancer.","volume":"19","author":"Kawamura","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"R30-20260831","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/cas.12963","article-title":"Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.","volume":"107","author":"Kawamura","year":"2016","journal-title":"Cancer Sci"},{"key":"R31-20260831","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R32-20260831","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2014.03.016","article-title":"Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.","volume":"85","author":"Kuiper","year":"2014","journal-title":"Lung Cancer"},{"key":"R33-20260831","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1186\/s12885-016-2902-0","article-title":"Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.","volume":"16","author":"Ko","year":"2016","journal-title":"BMC Cancer"},{"key":"R34-20260831","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting EGFR(L858R\/T790M) and EGFR(L858R\/T790M\/C797S) resistance mutations in NSCLC: current developments in medicinal chemistry.","volume":"38","author":"Lu","year":"2018","journal-title":"Med Res Rev"},{"key":"R35-20260831","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drup.2015.05.002","article-title":"Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors.","volume":"20","author":"Juchum","year":"2015","journal-title":"Drug Resist Updat"},{"key":"R36-20260831","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R37-20260831","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.3390\/cancers13194926","article-title":"Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring.","volume":"13","author":"Reita","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R38-20260831","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3389\/fonc.2020.01481","article-title":"An observational study of acquired EGFR T790M-dependent resistance to EGFR-TKI treatment in lung adenocarcinoma patients in Taiwan.","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"key":"R39-20260831","doi-asserted-by":"crossref","first-page":"e70921","DOI":"10.1002\/cam4.70921","article-title":"Strategies beyond 3rd EGFR-TKI acquired resistance: opportunities and challenges.","volume":"14","author":"Zhou","year":"2025","journal-title":"Cancer Med"},{"key":"R40-20260831","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases.","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R41-20260831","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2017.06.007","article-title":"Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.","volume":"110","author":"Shen","year":"2017","journal-title":"Lung Cancer"},{"key":"R42-20260831","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1002\/ijc.32025","article-title":"Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.","volume":"144","author":"Lin","year":"2019","journal-title":"Int J Cancer"},{"key":"R43-20260831","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s12094-019-02075-1","article-title":"Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.","volume":"21","author":"Gao","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"R44-20260831","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2019.01.012","article-title":"Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.","volume":"130","author":"Lee","year":"2019","journal-title":"Lung Cancer"},{"key":"R45-20260831","doi-asserted-by":"crossref","first-page":"451","DOI":"10.5507\/bp.2022.037","article-title":"An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.","volume":"166","author":"Chowaniecova","year":"2022","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"R46-20260831","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cpt.2024.07.001","article-title":"Epithelial-mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC).","volume":"3","author":"Dela Cruz","year":"2025","journal-title":"Cancer Pathog Ther"},{"key":"R47-20260831","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43556-022-00107-x","article-title":"Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.","volume":"3","author":"Wang","year":"2022","journal-title":"Mol Biomed"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:00:54Z","timestamp":1788195654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":47,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049283","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2025-09-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}